Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC.ALNY · Entity 3132 | President | August 03, 2023 | August 07, 2023 |
| Editas Medicine, Inc.EDIT · Entity 5502 | Director | May 30, 2024 | June 03, 2024 |
| Hemab Therapeutics Holdings, Inc.COAG · Entity 4476 | Director | April 30, 2026 | April 30, 2026 |
| Scholar Rock Holding CorpSRRK · Entity 3721 | Director · President of R&D | April 16, 2026 | April 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ALNYLAM PHARMACEUTICALS, INC.
Report date August 03, 2023 · Filed August 07, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 22,774 |
Ending reported balance
After 2023-08-04 transaction · row 8
8 source rows · reconciled sequenceRow 1 · 2023-08-03 · Grant · Acquired 5,082 · Balance 22,972 F1: On February 26, 2020, the reporting person was granted performance-based stock units (PSUs) in connection with the issuer 2019 year-end compensation review. The PSUs vest in separate installments based on the achievement of three specified performance measures as determined by the People, Culture and Compensation Committee of the issuer Board of Directors. The shares reported were issued to the reporting person upon vesting of one-third of the PSUs based on achievement of a corresponding performance measure relating to the issuer public reporting of the achievement of the first $2.5 billion in cumulative net product revenues determined in accordance with GAAP based solely upon the sales by the Company, including its affiliates and ex-U.S. distributions, of products discovered/developed by the Company. Row 2 · 2023-08-03 · Grant · Acquired 3,859 · Balance 26,831 F2: On February 24, 2021, the reporting person was granted performance-based stock units (PSUs) in connection with the issuer 2020 year-end compensation review. The PSUs vest in separate installments based on the achievement of four specified performance measures as determined by the People, Culture and Compensation Committee of the issuer Board of Directors. The shares reported were issued to the reporting person upon vesting of one-quarter of the PSUs based on achievement of a corresponding performance measure relating to the issuer public reporting of the achievement of the first $2.5 billion in cumulative net product revenues determined in accordance with GAAP based solely upon the sales by the Company, including its affiliates and ex-U.S. distributions, of products discovered/developed by the Company. Row 3 · 2023-08-04 · Sale · Disposed 771 · Balance 26,060 F3: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F4: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $184.01 to $185.01. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 4 · 2023-08-04 · Sale · Disposed 1,869 · Balance 24,191 F3: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F5: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $185.02 to $186.02. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 5 · 2023-08-04 · Sale · Disposed 1,107 · Balance 23,084 F3: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F6: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $186.03 to $187.02. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 6 · 2023-08-04 · Sale · Disposed 101 · Balance 22,983 F3: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F7: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $187.04 to $188.04. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 7 · 2023-08-04 · Sale · Disposed 17 · Balance 22,966 F8: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting event. F9: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $188.14 to $189.05. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 8 · 2023-08-04 · Sale · Disposed 192 · Balance 22,774 F3: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. |
| Common StockSEC Table I · non-derivative | Indirectby Managed Account | 515 |
Reported balance
Holding disclosure · report date 2023-08-03 · row 9
Holding and transaction disclosures are not merged.
1 source rowRow 9 · Balance 515 F10: Reflects shares of ALNY common stock acquired by the reporting person under the issuer 401(k) plan as a result of the issuer 401(k) matching contribution program. |
Filing footnotes · ownership attribution and instrument terms
F1: On February 26, 2020, the reporting person was granted performance-based stock units (PSUs) in connection with the issuer 2019 year-end compensation review. The PSUs vest in separate installments based on the achievement of three specified performance measures as determined by the People, Culture and Compensation Committee of the issuer Board of Directors. The shares reported were issued to the reporting person upon vesting of one-third of the PSUs based on achievement of a corresponding performance measure relating to the issuer public reporting of the achievement of the first $2.5 billion in cumulative net product revenues determined in accordance with GAAP based solely upon the sales by the Company, including its affiliates and ex-U.S. distributions, of products discovered/developed by the Company.
F2: On February 24, 2021, the reporting person was granted performance-based stock units (PSUs) in connection with the issuer 2020 year-end compensation review. The PSUs vest in separate installments based on the achievement of four specified performance measures as determined by the People, Culture and Compensation Committee of the issuer Board of Directors. The shares reported were issued to the reporting person upon vesting of one-quarter of the PSUs based on achievement of a corresponding performance measure relating to the issuer public reporting of the achievement of the first $2.5 billion in cumulative net product revenues determined in accordance with GAAP based solely upon the sales by the Company, including its affiliates and ex-U.S. distributions, of products discovered/developed by the Company.
F3: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.
F4: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $184.01 to $185.01. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F5: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $185.02 to $186.02. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F6: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $186.03 to $187.02. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F7: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $187.04 to $188.04. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F8: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting event.
F9: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $188.14 to $189.05. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F10: Reflects shares of ALNY common stock acquired by the reporting person under the issuer 401(k) plan as a result of the issuer 401(k) matching contribution program.
Editas Medicine, Inc.
Report date May 30, 2024 · Filed June 03, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.17 · Expires 2034-05-29 | Direct | 25,000 |
Reported balance
After 2024-05-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-05-30 · Grant · Acquired 25,000 · Balance 25,000 F1: This option was granted on May 30, 2024 and is scheduled to vest in full on May 30, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on May 30, 2024 and is scheduled to vest in full on May 30, 2025.
Hemab Therapeutics Holdings, Inc.
Report date April 30, 2026 · Filed April 30, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Warrants (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.97 · Expires 2034-05-07 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-04-30 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: The warrant was granted on May 8, 2024. The shares underlying the warrant vest over three years in equal monthly installments from January 1, 2024 through January 1, 2027. |
| Warrants (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.00 · Expires 2036-01-28 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-04-30 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F2: The warrant was granted on January 29, 2026. The shares underlying the warrant vest over three years in equal monthly installments from January 1, 2026 through January 1, 2029. |
Filing footnotes · ownership attribution and instrument terms
F1: The warrant was granted on May 8, 2024. The shares underlying the warrant vest over three years in equal monthly installments from January 1, 2024 through January 1, 2027.
F2: The warrant was granted on January 29, 2026. The shares underlying the warrant vest over three years in equal monthly installments from January 1, 2026 through January 1, 2029.
Scholar Rock Holding Corp
Report date April 16, 2026 · Filed April 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 630,542 |
Reported balance
After 2026-04-16 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-04-16 · Sale · Disposed 12,246 · Balance 630,542 F1: Represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of restricted stock units ("RSUs") on April 15, 2026. This sale is mandated by the Issuer's election under its equity incentive plans to require the reporting person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the reporting person. The shares vested pursuant to awards that were granted on April 27, 2025. Each RSU represents the contingent right to receive upon vesting of the RSU, one share of the Issuer's common stock. The shares subject to these RSU awards vest annually over four years, subject to a continued service relationship with the Issuer on the applicable vesting date. F2: Consists of 58,521 shares of common stock, 122,021 RSUs subject to time-based vesting conditions and 450,000 RSUs subject to performance- and time-based vesting conditions. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of restricted stock units ("RSUs") on April 15, 2026. This sale is mandated by the Issuer's election under its equity incentive plans to require the reporting person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the reporting person. The shares vested pursuant to awards that were granted on April 27, 2025. Each RSU represents the contingent right to receive upon vesting of the RSU, one share of the Issuer's common stock. The shares subject to these RSU awards vest annually over four years, subject to a continued service relationship with the Issuer on the applicable vesting date.
F2: Consists of 58,521 shares of common stock, 122,021 RSUs subject to time-based vesting conditions and 450,000 RSUs subject to performance- and time-based vesting conditions.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 11, 2021 Filed Feb 16, 2021 21:09 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantPerformance Stock Option 2017 (right to buy) · Derivative | 8,334 | $0.00 Strike: $119.13 | $0.00 |
DisclosureSEC source: 0001735276-21-000014 · edgardoc.xml · derivative · entry 5 Vaishnaw Akshay · CIK 0001458494 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 8,334 shares Expires 2028-03-01 F4 · kind: On March 1, 2018, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock in connection with the 2017 year-end compensation review. One third of the shares subject to the option vests upon the achievement of each of three specific clinical development, regulatory or commercial events. The People, Culture and Compensation Committee of the Board determined that the third performance criterion was met and the option vested as to the final one third of the shares as of February 11, 2021. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 21:09 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantCommon Stock | 5,416 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-21-000014 · edgardoc.xml · nonDerivative · entry 1 Vaishnaw Akshay · CIK 0001458494 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,535 F1 · kind: On February 28, 2019, the reporting person was granted performance-based restricted stock units (PSU) in connection with the 2018 year-end compensation review. One third of the PSU award vests upon the achievement of each of three specific clinical development, regulatory or commercial events. The People, Culture and Compensation Committee of the Board determined that the second performance criterion was met and an additional one-third of the PSU award vested as of February 11, 2021. Read SEC document |
| September 29, 2020 Filed Oct 1, 2020 20:03 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionStock Option (right to buy) · Derivative | 971 | $0.00 Strike: $42.22 | $0.00 |
DisclosureSEC source: 0001735276-20-000101 · edgardoc.xml · derivative · entry 4 Vaishnaw Akshay · CIK 0001458494 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,338 Underlying: Common Stock · 971 shares Expires 2026-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 04, 2019. F3 · derivative.exercise_date: The stock option vested as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter. Read SEC document |
| September 29, 2020 Filed Oct 1, 2020 20:03 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 971 | $140.00 | $135,940.00 |
DisclosureSEC source: 0001735276-20-000101 · edgardoc.xml · nonDerivative · entry 2 Vaishnaw Akshay · CIK 0001458494 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,119 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 04, 2019. Read SEC document |
| September 29, 2020 Filed Oct 1, 2020 20:03 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 971 | $42.22 | $40,995.62 |
DisclosureSEC source: 0001735276-20-000101 · edgardoc.xml · nonDerivative · entry 1 Vaishnaw Akshay · CIK 0001458494 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,090 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 04, 2019. Read SEC document |
| June 22, 2020 Filed Jun 24, 2020 20:02 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionStock Option (right to buy) · Derivative | 970 | $0.00 Strike: $42.22 | $0.00 |
DisclosureSEC source: 0001735276-20-000064 · edgardoc.xml · derivative · entry 8 Vaishnaw Akshay · CIK 0001458494 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,309 Underlying: Common Stock · 970 shares Expires 2026-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 04, 2019. F8 · derivative.exercise_date: The stock option vested as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter. Read SEC document |
| June 22, 2020 Filed Jun 24, 2020 20:02 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 195 | $152.97 | $29,829.15 |
DisclosureSEC source: 0001735276-20-000064 · edgardoc.xml · nonDerivative · entry 6 Vaishnaw Akshay · CIK 0001458494 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,119 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 04, 2019. F6 · price: Sale prices ranged from $152.84 to $153.34. Read SEC document |
| June 22, 2020 Filed Jun 24, 2020 20:02 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 334 | $152.22 | $50,841.48 |
DisclosureSEC source: 0001735276-20-000064 · edgardoc.xml · nonDerivative · entry 5 Vaishnaw Akshay · CIK 0001458494 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,314 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 04, 2019. F5 · price: Sale prices ranged from $151.58 to $152.56. Read SEC document |
| June 22, 2020 Filed Jun 24, 2020 20:02 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 180 | $150.34 | $27,061.20 |
DisclosureSEC source: 0001735276-20-000064 · edgardoc.xml · nonDerivative · entry 4 Vaishnaw Akshay · CIK 0001458494 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,648 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 04, 2019. F4 · price: Sale prices ranged from $150.18 to $150.53. Read SEC document |
| June 22, 2020 Filed Jun 24, 2020 20:02 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 83 | $149.09 | $12,374.47 |
DisclosureSEC source: 0001735276-20-000064 · edgardoc.xml · nonDerivative · entry 3 Vaishnaw Akshay · CIK 0001458494 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,828 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 04, 2019. F3 · price: Sale prices ranged from $149.07 to $149.96. Read SEC document |
| June 22, 2020 Filed Jun 24, 2020 20:02 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 178 | $148.48 | $26,429.44 |
DisclosureSEC source: 0001735276-20-000064 · edgardoc.xml · nonDerivative · entry 2 Vaishnaw Akshay · CIK 0001458494 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,911 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 04, 2019. F2 · price: Sale prices ranged from $148.01 to $148.78. Read SEC document |
| June 22, 2020 Filed Jun 24, 2020 20:02 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 970 | $42.22 | $40,953.40 |
DisclosureSEC source: 0001735276-20-000064 · edgardoc.xml · nonDerivative · entry 1 Vaishnaw Akshay · CIK 0001458494 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,089 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 04, 2019. Read SEC document |
| June 16, 2020 Filed Jun 18, 2020 20:23 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | GrantStock Option (right to buy) · Derivative | 13,000 | $0.00 Strike: $17.65 | $0.00 |
DisclosureSEC source: 0001179110-20-007535 · edgar.xml · derivative · entry 1 Vaishnaw Akshay · CIK 0001458494 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Stock · 13,000 shares Expires 2030-06-16 F1 · derivative.exercise_date: This option shall vest and become fully exercisable on the earlier of the first anniversary following the date of grant or the next scheduled Annual Meeting. Read SEC document |
| June 10, 2020 Filed Jun 12, 2020 20:15 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantStock Option (right to buy) · Derivative | 11,538 | $0.00 Strike: $27.49 | $0.00 |
DisclosureSEC source: 0001179110-20-007265 · edgar.xml · derivative · entry 1 Vaishnaw Akshay · CIK 0001458494 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,538 Underlying: Common Stock · 11,538 shares Expires 2030-06-09 F1 · derivative.exercise_date: This option was granted on June 10, 2020 and is scheduled to vest in full on June 10, 2021. Read SEC document |
| April 20, 2020 Filed Apr 22, 2020 20:06 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionStock Option (right to buy) · Derivative | 971 | $0.00 Strike: $42.22 | $0.00 |
DisclosureSEC source: 0001735276-20-000055 · edgardoc.xml · derivative · entry 6 Vaishnaw Akshay · CIK 0001458494 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,279 Underlying: Common Stock · 971 shares Expires 2026-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 04, 2019. F3 · derivative.exercise_date: The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter. Read SEC document |
| April 20, 2020 Filed Apr 22, 2020 20:06 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionPerformance Stock Option 2016 (right to buy) · Derivative | 21,000 | $0.00 Strike: $42.22 | $0.00 |
DisclosureSEC source: 0001735276-20-000055 · edgardoc.xml · derivative · entry 5 Vaishnaw Akshay · CIK 0001458494 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,000 shares Expires 2026-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 04, 2019. Read SEC document |
| April 20, 2020 Filed Apr 22, 2020 20:06 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 21,971 | $140.00 | $3,075,940.00 |
DisclosureSEC source: 0001735276-20-000055 · edgardoc.xml · nonDerivative · entry 3 Vaishnaw Akshay · CIK 0001458494 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,119 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 04, 2019. Read SEC document |
| April 20, 2020 Filed Apr 22, 2020 20:06 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 971 | $42.22 | $40,995.62 |
DisclosureSEC source: 0001735276-20-000055 · edgardoc.xml · nonDerivative · entry 2 Vaishnaw Akshay · CIK 0001458494 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,090 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 04, 2019. Read SEC document |
| April 20, 2020 Filed Apr 22, 2020 20:06 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 21,000 | $42.22 | $886,620.00 |
DisclosureSEC source: 0001735276-20-000055 · edgardoc.xml · nonDerivative · entry 1 Vaishnaw Akshay · CIK 0001458494 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,119 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 04, 2019. Read SEC document |
| April 07, 2020 Filed Apr 9, 2020 20:03 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Tax withholdingCommon Stock | 98 | $106.52 | $10,438.96 |
DisclosureSEC source: 0001735276-20-000045 · edgardoc.xml · nonDerivative · entry 3 Vaishnaw Akshay · CIK 0001458494 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,119 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the PSU award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting event. Read SEC document |
| April 07, 2020 Filed Apr 9, 2020 20:03 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Tax withholdingCommon Stock | 2,415 | $104.75 | $252,971.25 |
DisclosureSEC source: 0001735276-20-000045 · edgardoc.xml · nonDerivative · entry 2 Vaishnaw Akshay · CIK 0001458494 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,217 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the PSU award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting event. Read SEC document |
| April 07, 2020 Filed Apr 9, 2020 20:03 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantCommon Stock | 5,417 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-20-000045 · edgardoc.xml · nonDerivative · entry 1 Vaishnaw Akshay · CIK 0001458494 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,632 F1 · kind: On February 28, 2019, the reporting person was granted performance-based restricted stock units (PSU) in connection with the 2018 year-end compensation review. This PSU award vests in three equal installments upon the later of one year from the date of grant and the achievement of each of three specific clinical development, regulatory or commercial events. One third of the shares subject to release under the PSU award vested upon the filing by the Company of its fourth NDA with the FDA, as determined by the compensation committee of the Company effective April 7, 2020. Read SEC document |
| February 26, 2020 Filed Feb 28, 2020 21:06 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantStock Option (right to buy) · Derivative | 27,623 | $0.00 Strike: $118.05 | $0.00 |
DisclosureSEC source: 0001735276-20-000031 · edgardoc.xml · derivative · entry 1 Vaishnaw Akshay · CIK 0001458494 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,623 Underlying: Common Stock · 27,623 shares Expires 2030-02-25 F1 · shares: Represents the time-vested stock option portion of the reporting person's Annual Equity Award for 2019. The reporting person also received 15,248 performance stock units that will vest upon the achievement of three specific performance conditions, which will be reported on a Form 4 if and when each performance condition is met and the performance stock units vest. F2 · derivative.exercise_date: The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter. Read SEC document |
| February 07, 2020 Filed Feb 11, 2020 21:08 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionStock Option (right to buy) · Derivative | 18,750 | $0.00 Strike: $42.22 | $0.00 |
DisclosureSEC source: 0001735276-20-000009 · edgardoc.xml · derivative · entry 6 Vaishnaw Akshay · CIK 0001458494 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,250 Underlying: Common Stock · 18,750 shares Expires 2026-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 04, 2019. F3 · derivative.exercise_date: The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter. Read SEC document |
| February 07, 2020 Filed Feb 11, 2020 21:08 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionPerformance Stock Option 2016 (right to buy) · Derivative | 4,000 | $0.00 Strike: $42.22 | $0.00 |
DisclosureSEC source: 0001735276-20-000009 · edgardoc.xml · derivative · entry 5 Vaishnaw Akshay · CIK 0001458494 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 Underlying: Common Stock · 4,000 shares Expires 2026-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 04, 2019. Read SEC document |
| February 07, 2020 Filed Feb 11, 2020 21:08 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 23,708 | $125.00 | $2,963,500.00 |
DisclosureSEC source: 0001735276-20-000009 · edgardoc.xml · nonDerivative · entry 3 Vaishnaw Akshay · CIK 0001458494 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,215 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 04, 2019. Read SEC document |
| February 07, 2020 Filed Feb 11, 2020 21:08 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 4,000 | $42.22 | $168,880.00 |
DisclosureSEC source: 0001735276-20-000009 · edgardoc.xml · nonDerivative · entry 2 Vaishnaw Akshay · CIK 0001458494 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,923 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 04, 2019. Read SEC document |
| February 07, 2020 Filed Feb 11, 2020 21:08 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 18,750 | $42.22 | $791,625.00 |
DisclosureSEC source: 0001735276-20-000009 · edgardoc.xml · nonDerivative · entry 1 Vaishnaw Akshay · CIK 0001458494 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,923 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 04, 2019. Read SEC document |
| December 23, 2019 Filed Dec 26, 2019 21:04 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantPerformance Stock Option 2017 (right to buy) · Derivative | 8,333 | $0.00 Strike: $119.13 | $0.00 |
DisclosureSEC source: 0001735276-19-000123 · edgardoc.xml · derivative · entry 1 Vaishnaw Akshay · CIK 0001458494 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,666 Underlying: Common Stock · 8,333 shares Expires 2028-03-01 F1 · kind: On March 1, 2018, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One third of the shares subject to the option vest upon the achievement of each of three specific clinical development, regulatory or commercial events, as approved by our compensation committee. The compensation committee of the Company determined that the second performance criterion was met and the option vested as to the second one third of the shares as of December 23, 2019. Read SEC document |
| November 22, 2019 Filed Nov 26, 2019 21:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantPerformance Stock Option 2017 (right to buy) · Derivative | 8,333 | $0.00 Strike: $119.13 | $0.00 |
DisclosureSEC source: 0001735276-19-000106 · edgardoc.xml · derivative · entry 1 Vaishnaw Akshay · CIK 0001458494 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,333 Underlying: Common Stock · 8,333 shares Expires 2028-03-01 F1 · kind: On March 1, 2018, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One third of the shares subject to the option vest upon the achievement of each of three specific clinical development, regulatory or commercial events, as approved by our compensation committee. The compensation committee of the Company determined that the first performance criterion was met on November 22, 2019 and the option vested as to the first one third of the shares as of such date. Read SEC document |
| August 06, 2019 Filed Aug 7, 2019 20:17 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantPerformance Stock Option 2016 (right to buy) · Derivative | 6,250 | $0.00 Strike: $42.22 | $0.00 |
DisclosureSEC source: 0001735276-19-000085 · edgardoc.xml · derivative · entry 4 Vaishnaw Akshay · CIK 0001458494 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 6,250 shares Expires 2026-12-20 F3 · kind: On December 20, 2016, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One quarter of the shares subject to the option vested upon the achievement of each of four specific clinical development, regulatory or commercial events, as approved by our compensation committee. The compensation committee of the Company determined that the fourth performance criterion was met effective as of August 6, 2019 and the option vested as to the final one-quarter of the shares as of such date. Read SEC document |
| August 06, 2019 Filed Aug 7, 2019 20:17 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantPerformance Stock Option 2015 (right to buy) · Derivative | 7,500 | $0.00 Strike: $88.95 | $0.00 |
DisclosureSEC source: 0001735276-19-000085 · edgardoc.xml · derivative · entry 3 Vaishnaw Akshay · CIK 0001458494 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 7,500 shares Expires 2025-12-18 F2 · kind: On December 18, 2015, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One quarter of the shares subject to the option vested upon the achievement of each of four specific clinical development or commercial events, as approved by our compensation committee. The compensation committee of the Company determined that the fourth performance criterion was met effective as of August 6, 2019 and the option vested as to the final one-quarter of the shares as of such date. Read SEC document |
| July 11, 2019 Filed Aug 7, 2019 20:17 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | OtherCommon Stock | 48 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-19-000085 · edgardoc.xml · nonDerivative · entry 1 Vaishnaw Akshay · CIK 0001458494 · President, R&D 10b5-1 filing: Not disclosed Ownership: Indirect · by Managed Account Disclosed balance after: 515 F1 · kind: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. F1 · price: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. F1 · ownership.nature: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. Read SEC document |
| June 12, 2019 Filed Jun 14, 2019 20:27 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantStock Option (right to buy) · Derivative | 11,538 | $0.00 Strike: $21.74 | $0.00 |
DisclosureSEC source: 0001179110-19-007675 · edgar.xml · derivative · entry 1 Vaishnaw Akshay · CIK 0001458494 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,538 Underlying: Common Stock · 11,538 shares Expires 2029-06-11 F1 · derivative.exercise_date: This option was granted on June 12, 2019 and is scheduled to vest in full on June 12, 2020. Read SEC document |
| June 05, 2019 Filed Jun 7, 2019 20:03 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantPerformance Stock Option 2016 (right to buy) · Derivative | 6,250 | $0.00 Strike: $42.22 | $0.00 |
DisclosureSEC source: 0001735276-19-000045 · edgardoc.xml · derivative · entry 4 Vaishnaw Akshay · CIK 0001458494 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,750 Underlying: Common Stock · 6,250 shares Expires 2026-12-20 F2 · kind: On December 20, 2016, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One quarter of the shares subject to the option will vest upon the achievement of each of four specific clinical development, regulatory or commercial events, as approved by our compensation committee. On June 6, 2019, the compensation committee of the Company determined the third performance criterion had been met on June 5, 2019 and the option vested as to one-quarter of the shares as of such date. Read SEC document |
| May 21, 2019 Filed May 24, 2019 01:42 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | GrantStock Option (Right to Buy) · Derivative | 20,316 | $0.00 Strike: $21.21 | $0.00 |
DisclosureSEC source: 0001104659-19-031596 · a4.xml · derivative · entry 1 Vaishnaw Akshay · CIK 0001458494 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,316 Underlying: Common Stock · 20,316 shares Expires 2029-05-21 F1 · derivative.exercise_date: This option vests monthly over three (3) years, with the first monthly amount vesting June 21, 2019. Read SEC document |
| April 09, 2019 Filed Jun 7, 2019 20:03 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | OtherCommon Stock | 51 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-19-000045 · edgardoc.xml · nonDerivative · entry 2 Vaishnaw Akshay · CIK 0001458494 · President, R&D 10b5-1 filing: Not disclosed Ownership: Indirect · by Managed Account Disclosed balance after: 467 F1 · kind: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. F1 · price: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. F1 · ownership.nature: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. Read SEC document |
| February 28, 2019 Filed Mar 1, 2019 23:10 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantStock Option (right to buy) · Derivative | 32,500 | $0.00 Strike: $85.00 | $0.00 |
DisclosureSEC source: 0001735276-19-000032 · edgardoc.xml · derivative · entry 1 Vaishnaw Akshay · CIK 0001458494 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,500 Underlying: Common Stock · 32,500 shares Expires 2029-02-27 F1 · shares: Represents the time-vested portion of the reporting person's Annual Stock Option Award for 2018. The reporting person also received 16,250 performance stock units that will vest upon the achievement of three specific performance conditions, which will be reported on a Form 4 if and when each performance condition is met and the option vests. F2 · derivative.exercise_date: The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter. Read SEC document |
| October 18, 2018 Filed Jun 7, 2019 20:03 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | OtherCommon Stock | 21 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-19-000045 · edgardoc.xml · nonDerivative · entry 1 Vaishnaw Akshay · CIK 0001458494 · President, R&D 10b5-1 filing: Not disclosed Ownership: Indirect · by Managed Account Disclosed balance after: 416 F1 · kind: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. F1 · price: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. F1 · ownership.nature: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. Read SEC document |
| September 27, 2018 Filed Sep 28, 2018 20:57 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantPerformance Stock Option 2016 (right to buy) · Derivative | 6,250 | $0.00 Strike: $42.22 | $0.00 |
DisclosureSEC source: 0001735276-18-000074 · edgardoc.xml · derivative · entry 2 Vaishnaw Akshay · CIK 0001458494 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 6,250 shares Expires 2026-12-20 F2 · kind: On December 20, 2016, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One quarter of the shares subject to the option will vest upon the achievement of each of four specific clinical development, regulatory or commercial events, as approved by our compensation committee. Effective September 27, 2018, the compensation committee of the Company determined the second performance criterion had been met and the option vested as to one-quarter of the shares. Read SEC document |
| September 27, 2018 Filed Sep 28, 2018 20:57 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantPerformance Stock Option 2015 (right to buy) · Derivative | 7,500 | $0.00 Strike: $88.95 | $0.00 |
DisclosureSEC source: 0001735276-18-000074 · edgardoc.xml · derivative · entry 1 Vaishnaw Akshay · CIK 0001458494 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 7,500 shares Expires 2025-12-18 F1 · kind: On December 18, 2015, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One quarter of the shares subject to the option will vest upon the achievement of each of four specific clinical development and regulatory events, as approved by our compensation committee. Effective September 27, 2018, the compensation committee of the Company determined the third performance criterion had been met and the option vested as to one-quarter of the shares. Read SEC document |
| August 21, 2018 Filed Aug 23, 2018 20:15 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantPerformance Stock Option 2015 (right to buy) · Derivative | 7,500 | $0.00 Strike: $88.95 | $0.00 |
DisclosureSEC source: 0001735276-18-000060 · edgardoc.xml · derivative · entry 1 Vaishnaw Akshay · CIK 0001458494 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 7,500 shares Expires 2025-12-18 F1 · kind: On December 18, 2015, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One quarter of the shares subject to the option will vest upon the achievement of each of four specific clinical development or commercial events, as approved by our compensation committee. Effective August 21, 2018, the compensation committee of the Company determined the second performance criterion had been met and the option vested as to one-quarter of the shares. Read SEC document |
| August 13, 2018 Filed Aug 14, 2018 22:55 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Tax withholdingCommon Stock | 766 | $90.95 | $69,667.70 |
DisclosureSEC source: 0001325812-18-000030 · primary_doc.xml · nonDerivative · entry 2 Vaishnaw Akshay · CIK 0001458494 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,173 Read SEC document |
| August 13, 2018 Filed Aug 14, 2018 22:55 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantCommon Stock | 1,724 | $0.00 | $0.00 |
DisclosureSEC source: 0001325812-18-000030 · primary_doc.xml · nonDerivative · entry 1 Vaishnaw Akshay · CIK 0001458494 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,939 F1 · kind: On January 4, 2016, the reporting person was granted a restricted stock unit (RSU) to purchase shares of ALNY common stock. The shares subject to release vest upon the commercial launch of Alnylams first internally developed product, as approved by our compensation committee. Effective August 13, 2018, the compensation committee of the Company determined the performance criterion has been met and the RSU shares have vested. Read SEC document |
| August 10, 2018 Filed Aug 14, 2018 22:55 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantPerformance Based Stock Option 2014 (right to buy) · Derivative | 11,707 | $0.00 Strike: $96.45 | $0.00 |
DisclosureSEC source: 0001325812-18-000030 · primary_doc.xml · derivative · entry 6 Vaishnaw Akshay · CIK 0001458494 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,125 Underlying: Common Stock · 11,707 shares Expires 2024-12-17 F4 · kind: On December 17, 2014, the reporting person was granted a performance based stock option to purchase shares of ALNY Common Stock. One-third of the shares subject to the option will vest upon the achievement of each of three specific clinical development and regulatory events, as approved by our compensation committee. Effective August 10, 2018, the compensation committee of the Company determined the final performance criteria had been met and the option vested as to the final third of the award. Read SEC document |
| August 10, 2018 Filed Aug 14, 2018 22:55 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantPerformance Based Stock Option 2013 (right to buy) · Derivative | 10,832 | $0.00 Strike: $63.00 | $0.00 |
DisclosureSEC source: 0001325812-18-000030 · primary_doc.xml · derivative · entry 5 Vaishnaw Akshay · CIK 0001458494 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,500 Underlying: Common Stock · 10,832 shares Expires 2023-12-18 F3 · kind: On December 18, 2013, the reporting person was granted a performance based stock option to purchase shares of ALNY Common Stock. One-third of the shares subject to the option will vest upon the achievement of each of three specific clinical development and regulatory events, as approved by our compensation committee. Effective August 10, 2018, the compensation committee of the Company determined the final performance criteria had been met and the option will vest as to the final third of the award. Read SEC document |
| July 10, 2018 Filed Aug 14, 2018 22:55 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | OtherCommon Stock | 29 | $0.00 | $0.00 |
DisclosureSEC source: 0001325812-18-000030 · primary_doc.xml · nonDerivative · entry 4 Vaishnaw Akshay · CIK 0001458494 · President, R&D 10b5-1 filing: Not disclosed Ownership: Indirect · by Managed Account Disclosed balance after: 395 F2 · kind: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. F2 · price: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. F2 · ownership.nature: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. Read SEC document |
| June 15, 2018 Filed Jun 19, 2018 20:04 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantStock Option (right to buy) · Derivative | 11,538 | $0.00 Strike: $37.50 | $0.00 |
DisclosureSEC source: 0001179110-18-008770 · edgar.xml · derivative · entry 1 Vaishnaw Akshay · CIK 0001458494 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,538 Underlying: Common Stock · 11,538 shares Expires 2028-06-14 F1 · derivative.exercise_date: This option was granted on June 15, 2018 and is scheduled to vest in full on June 15, 2019. Read SEC document |
| April 16, 2018 Filed Aug 14, 2018 22:55 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | OtherCommon Stock | 28 | $0.00 | $0.00 |
DisclosureSEC source: 0001325812-18-000030 · primary_doc.xml · nonDerivative · entry 3 Vaishnaw Akshay · CIK 0001458494 · President, R&D 10b5-1 filing: Not disclosed Ownership: Indirect · by Managed Account Disclosed balance after: 366 F2 · kind: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. F2 · price: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. F2 · ownership.nature: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. Read SEC document |
| March 14, 2018 Filed Mar 16, 2018 21:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionStock Option (right to buy) · Derivative | 44,641 | $0.00 Strike: $18.66 | $0.00 |
DisclosureSEC source: 0001553878-18-000027 · edgardoc.xml · derivative · entry 13 Vaishnaw Akshay · CIK 0001458494 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 44,641 shares Expires 2022-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 10, 2018. F9 · derivative.exercise_date: The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.